Neogenomics

The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer.

The company said it intends to use the proceeds for general corporate purposes and to repay borrowings under its term loan facility.

NeoGenomics noted that test volumes had been disrupted by the COVID-19 pandemic, leading to reduced growth in the company.

Clinical test volume at the company is expected to grow 7 percent year over year but decreased significantly at the end of March due to the COVID-19 pandemic.

The three-year contract secures standardized pricing for HPG-affiliated facilities across the US and offers access to NeoGenomics' testing services.

The company's Q4 revenues exceeded Wall Street estimates and the clinical genetic testing and pharma services businesses outperformed expectations. 

Test volumes, revenues per test and costs per test improved during the quarter, the company said.

The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019. 

The index's gain was well above the 13 percent increase of 2018, and almost reached the 39 percent increase it saw in 2017.